VANDA PHARMACEUTICALS INC's ticker is VNDA and the CUSIP is 921659108. A total of 190 filers reported holding VANDA PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 0.92 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,319,056 | -19.5% | 768,300 | +22.8% | 0.01% | -18.2% |
| Q2 2023 | $4,123,363 | +5.2% | 625,700 | +8.4% | 0.01% | +10.0% |
| Q1 2023 | $3,920,546 | +17.0% | 577,400 | +27.3% | 0.01% | +11.1% |
| Q4 2022 | $3,350,626 | -22.5% | 453,400 | +3.6% | 0.01% | -30.8% |
| Q3 2022 | $4,325,000 | -32.3% | 437,800 | -25.3% | 0.01% | -27.8% |
| Q2 2022 | $6,384,000 | -3.7% | 585,700 | -0.1% | 0.02% | 0.0% |
| Q1 2022 | $6,628,000 | -22.8% | 586,000 | +7.1% | 0.02% | -18.2% |
| Q4 2021 | $8,589,000 | +29.1% | 547,400 | +41.0% | 0.02% | +29.4% |
| Q3 2021 | $6,655,000 | -24.4% | 388,300 | -5.1% | 0.02% | -26.1% |
| Q2 2021 | $8,800,000 | +80.1% | 409,100 | +25.8% | 0.02% | +76.9% |
| Q1 2021 | $4,886,000 | +37.9% | 325,300 | +20.7% | 0.01% | +44.4% |
| Q4 2020 | $3,543,000 | +17.6% | 269,600 | -13.5% | 0.01% | 0.0% |
| Q3 2020 | $3,012,000 | -40.4% | 311,800 | -29.4% | 0.01% | -40.0% |
| Q2 2020 | $5,052,000 | +16.9% | 441,600 | +5.8% | 0.02% | -11.8% |
| Q1 2020 | $4,322,000 | -31.1% | 417,200 | +9.2% | 0.02% | +13.3% |
| Q4 2019 | $6,270,000 | +24.9% | 382,100 | +1.1% | 0.02% | +25.0% |
| Q3 2019 | $5,019,000 | -15.2% | 377,900 | -10.0% | 0.01% | -20.0% |
| Q2 2019 | $5,919,000 | +6.7% | 420,100 | +39.3% | 0.02% | +7.1% |
| Q1 2019 | $5,548,000 | -7.2% | 301,500 | +31.8% | 0.01% | -12.5% |
| Q4 2018 | $5,976,000 | -4.3% | 228,700 | -15.9% | 0.02% | +6.7% |
| Q3 2018 | $6,242,000 | +9.2% | 272,000 | -9.4% | 0.02% | 0.0% |
| Q2 2018 | $5,717,000 | +146.7% | 300,100 | +118.3% | 0.02% | +150.0% |
| Q1 2018 | $2,317,000 | +42.2% | 137,500 | +28.3% | 0.01% | +50.0% |
| Q4 2017 | $1,629,000 | -39.8% | 107,200 | -29.1% | 0.00% | -50.0% |
| Q3 2017 | $2,708,000 | +12.9% | 151,300 | +2.9% | 0.01% | 0.0% |
| Q2 2017 | $2,398,000 | +49.9% | 147,100 | +28.7% | 0.01% | +60.0% |
| Q1 2017 | $1,600,000 | -37.6% | 114,300 | -28.9% | 0.01% | -50.0% |
| Q4 2016 | $2,565,000 | +19.6% | 160,800 | +24.7% | 0.01% | +11.1% |
| Q3 2016 | $2,145,000 | +247.6% | 128,900 | +133.9% | 0.01% | +200.0% |
| Q2 2016 | $617,000 | – | 55,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 1,532,000 | $27,423,000 | 3.23% |
| Stonepine Capital Management, LLC | 300,000 | $5,370,000 | 3.16% |
| Palo Alto Investors LP | 4,155,670 | $74,386,000 | 3.13% |
| GREAT POINT PARTNERS LLC | 497,531 | $8,906,000 | 1.73% |
| Avoro Capital Advisors LLC | 988,270 | $17,690,000 | 1.37% |
| UNIVERSITY OF NOTRE DAME DU LAC | 157,781 | $2,824,000 | 0.79% |
| Birchview Capital, LP | 68,000 | $1,217,000 | 0.63% |
| Cheyne Capital Management (UK) LLP | 74,000 | $1,323,000 | 0.48% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 352,604 | $6,311,000 | 0.43% |
| 361 CAPITAL LLC | 119,554 | $2,140,000 | 0.41% |